Table 1.

Characteristics of the patients treated with CIMAvax-EGF. Most patients had ECOG-1, adenocarcinoma histology and partial or stable disease after completing front line therapy.

Patient Characteristics		No (106)	%
Age	65 years	50	47.2
	65 years and more	56	52.8
Gender	Male	62	58.5
	Female	44	48.5
ECOG	0	22	20.8
	1	82	77.4
	2	2	1.9
Histology	Adenocarcinoma	66	62.3
	Squamous cell	28	26.4
	Large cell carcinoma	12	11.3
Stage	IIIB	63	59.4
	IV	43	40.6
First line therapy	Chemotherapy Radiotherapy	63	59.4
	Chemotherapy	43	40.6
Chemotherapy	Cisplatin/etoposide	83	78.3
	Carboplatin/paclitaxel	13	12.2
	Carboplatin / gemcitabine	10	9.4
Response to first-line treatment	Complete response	8	7.5
	Partial response	60	56.6
	Stable disease	38	35.8